MEET THE TEAM
Pacific Bridge NY is led by an experienced investment, clinical, and operating team, supported by an advisory council and clinical experts from leading academic and biopharmaceutical institutions.
Marc S. Appel
Managing Partner
Marc is the founder and Managing Partner of Pacific Bridge NY. Previously, he founded the drug investment and development platform Orange Grove Bio and served as its CEO where he helped launch and lead multiple portfolio companies, including IpiNovyx Bio, Asalyxa Bio, and Allonix Therapeutics.
Before founding Pacific Bridge NY and Orange Grove Bio, Marc was a healthcare investor at Marathon Asset Management, where he invested across the capital structure and helped develop a structured healthcare and royalty investing strategy. He began his career at McKinsey & Company.
Marc is also an active advisor to university innovation programs, including the Frankel Fund at the University of Michigan, Yale’s Blavatnik Program, Cornell University’s tech transfer office, and the Dartmouth Innovations Accelerator for Cancer. He frequently speaks at industry conferences and academic institutions and is the co-author of a Harvard Business School case on Imprimis Pharmaceuticals.
Throughout his career, Marc has founded and invested in many biotech companies and negotiated, structured, and led numerous partnerships with large pharmaceutical companies and has served on the boards of biotechs across stages, therapeutic areas, and modalities.
He holds a B.A. from Yale University, a J.D. from Harvard Law School, and an M.B.A. from Harvard Business School. He is a member of the New York Bar.
Joe Walker
Partner
Joe is a Partner of Pacific Bridge NY. He brings more than 25 years of executive leadership experience across global pharmaceutical and biotechnology companies, with deep expertise in early drug development, translational strategy, and cross-functional program leadership.
Previously, Joe held senior leadership roles at Bristol Myers Squibb, Celgene, and Daiichi Sankyo, where he led programs from candidate nomination through IND filing and clinical proof-of-concept. At BMS, he served as Vice President and Senior Global Program Leader for Neuroscience, with full accountability for the development of the neuroscience portfolio. Across his career, he has filed more than ten INDs and helped build foundational R&D capabilities from the ground up.
Before joining BMS, Joe was Executive Director of Global Project Leadership at Celgene, where he led large, global, matrixed development teams and was accountable to executive governance for overall program vision, development strategy, and execution. He served as Global Program Lead on multiple oncology assets, including bispecific antibodies, monoclonal antibodies, targeted protein degraders, and small-molecule inhibitors.
Earlier in his career at Daiichi Sankyo, Joe held leadership roles in Companion Diagnostics, Pharmacogenomics, and Clinical Pharmacology, where he designed and executed innovative early clinical development strategies from first-in-human through proof-of-concept. He has deep technical expertise in clinical pharmacology, biomarker strategy, pharmacogenomics, and personalized medicine, with therapeutic experience spanning neuroscience, neurodegeneration, oncology, thrombosis, and diabetes.
Joe is the author or co-author of multiple peer-reviewed publications in leading medical journals, including The Lancet and The New England Journal of Medicine, and is the recipient of the 2010 McKeen Cattell Memorial Award for Outstanding Manuscript in the Journal of Clinical Pharmacology. He is widely recognized as a leader of leaders with extensive experience guiding complex programs through critical development inflection points.
He holds a PharmD from the University of Tennessee and completed postgraduate training including a residency and a post-doctoral fellowship in pharmacogenomics.
Min (Winnie) Wang
Partner
Winnie is a Partner of Pacific Bridge NY. She brings over 20 years of experience in pharmaceutical and life sciences business development, with deep expertise in partnering, licensing, and alliance management, and a particular focus on facilitating complex cross-border transactions..
Previously, Winnie held senior business development and alliance leadership roles at Roche, Sanofi, Fosun Pharma, and GeneScience Pharmaceuticals. Most recently, she served as Partnering and Alliance Management Director at Roche, where she led international partnering initiatives and alliance management efforts. At Sanofi, she was Asia Alliance Director for Business Development and Licensing, responsible for regional partnering strategy and execution across multiple therapeutic areas.
Before joining Sanofi in her alliance leadership role, Winnie spent more than six years at Sanofi in External Innovation and Business Development, where she sourced, structured, negotiated, and executed licensing and collaboration agreements with global biotech and pharmaceutical partners. She played a key role in advancing Sanofi’s external innovation strategy across Asia and strengthening long-term strategic partnerships.
Earlier in her career, Winnie served as Business Development Director at Fosun Pharma and Head of Business Development at GeneScience Pharmaceuticals, where she led corporate strategy, international business development, and cross-border transaction execution. Across her roles, she has built a strong track record of identifying high-quality assets and partners and translating strategic priorities into executed transactions.
Throughout her career, Winnie has been recognized for her ability to bridge global organizations, cultures, and deal structures, and for her leadership in driving successful international collaborations within the pharmaceutical and life sciences ecosystem.
Jarrat Jordan
Venture Advisor
Jarrat is a Venture Advisor to Pacific Bridge NY. He brings over 20 years of experience in immunology research and drug discovery across large pharmaceutical companies and innovative biotechnology organizations, with deep expertise spanning innate and adaptive immunity, translational biology, and therapeutic area strategy.
Previously, Jarrat has held senior scientific and research leadership roles at CSL, Dragonfly Therapeutics, Seeker Biologics, and Johnson & Johnson. He currently serves as Research Therapeutic Area Lead for Immunology, Transplant, and Vaccines at CSL, where he is responsible for setting scientific strategy and advancing research programs across multiple immune-mediated disease areas.
Before joining CSL, Jarrat was Vice President of Immunology and Translation at Dragonfly Therapeutics, where he led immunology and translational biology efforts supporting the advancement of novel immunotherapeutic platforms. He also served as Vice President and Head of Biology at Seeker Biologics, overseeing biology strategy and execution across early-stage discovery programs.
Earlier in his career, Jarrat spent nearly two decades at Johnson & Johnson and the Janssen Pharmaceutical Companies, where he progressed through roles of increasing responsibility including Senior Director of Immunology Scientific Innovation, Director of Lupus Biomarkers, Associate Scientific Director, and Principal Scientist. During this time, he led discovery and biomarker programs in immunology and autoimmune diseases and contributed to the advancement of multiple research-stage and clinical programs.
Throughout his career, Jarrat has been recognized for his ability to translate deep biological insight into therapeutic strategy, advise on immunology-driven investment and development decisions, and support the advancement of innovative programs from discovery through early clinical development.
He holds a Ph.D. in Microbiology from the University of Georgia and a B.S. in Biology from Valdosta State University.
Taylor Negrete
Head of Investor Relations & Operations
Taylor is the Head of Investor Relations & Operations at Pacific Bridge NY. She leads the firm’s investor relations, strategic communications, and operational functions, and plays a central role in supporting the firm’s growth, investment activities, and long-term strategy.
Prior to Pacific Bridge NY, Taylor worked alongside Marc Appel at Orange Grove Bio, supporting company formation, investment activities, and portfolio company operations across the platform. In this role, she was deeply involved in coordinating portfolio initiatives, supporting investment and partnership processes, and acting as a strategic and operational partner to the CEO across a growing drug development and investment organization.
Earlier in her career, Taylor held operations, executive management, and client-facing roles across startup and technology-driven organizations, including Linear Technology, where she gained experience in international business and stakeholder engagement. Throughout her career, she has been recognized for her ability to build trusted relationships, bring structure to complex environments, and operate as a strategic partner to senior leadership.
She holds a B.S. in Public Relations from San José State University.
Jordan Schultz
Investment Associate
Jordan is an Investment Associate at Pacific Bridge NY. Her experience spans life sciences IP, drug development, licensing, and clinical research across diverse modalities.
Managed technology portfolios and licensing at Yale University and the University of Georgia, supporting startup formation. Built diligence frameworks for early clinical and preclinical assets, with a focus on oncology, immunology, and platform technologies.